14.07
price down icon35.94%   -7.895
after-market After Hours: 13.37 -0.705 -5.01%
loading
Sarepta Therapeutics Inc stock is traded at $14.07, with a volume of 76.62M. It is down -35.94% in the last 24 hours and down -32.23% over the past month. Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
See More
Previous Close:
$21.97
Open:
$16.975
24h Volume:
76.62M
Relative Volume:
11.49
Market Cap:
$1.38B
Revenue:
$2.23B
Net Income/Loss:
$-248.39M
P/E Ratio:
-5.2323
EPS:
-2.69
Net Cash Flow:
$-697.55M
1W Performance:
-22.54%
1M Performance:
-32.23%
6M Performance:
-88.07%
1Y Performance:
-90.21%
1-Day Range:
Value
$12.81
$19.18
1-Week Range:
Value
$12.81
$22.86
52-Week Range:
Value
$12.81
$150.48

Sarepta Therapeutics Inc Stock (SRPT) Company Profile

Name
Name
Sarepta Therapeutics Inc
Name
Phone
617-274-4000
Name
Address
215 FIRST STREET, CAMBRIDGE, MA
Name
Employee
1,372
Name
Twitter
@sarepta
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
SRPT's Discussions on Twitter

Compare SRPT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SRPT
Sarepta Therapeutics Inc
14.07 1.79B 2.23B -248.39M -697.55M -2.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.81 120.40B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
542.52 61.30B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.53 41.06B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
564.59 34.29B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.55 27.09B 3.81B -644.79M -669.77M -6.24

Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-18-25 Downgrade Needham Buy → Hold
Jun-20-25 Downgrade William Blair Outperform → Mkt Perform
Jun-18-25 Downgrade TD Cowen Buy → Hold
Jun-17-25 Initiated Wolfe Research Peer Perform
Jun-16-25 Downgrade BMO Capital Markets Outperform → Market Perform
Jun-16-25 Downgrade BofA Securities Buy → Neutral
Jun-16-25 Downgrade Cantor Fitzgerald Overweight → Neutral
Jun-16-25 Downgrade H.C. Wainwright Neutral → Sell
Jun-16-25 Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-16-25 Downgrade Piper Sandler Overweight → Neutral
Jun-06-25 Upgrade Scotiabank Sector Perform → Sector Outperform
May-08-25 Downgrade Evercore ISI Outperform → In-line
Apr-11-25 Initiated Wells Fargo Overweight
Apr-02-25 Upgrade H.C. Wainwright Sell → Neutral
Mar-31-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-11-25 Initiated Deutsche Bank Hold
Nov-27-24 Reiterated Needham Buy
Nov-25-24 Initiated H.C. Wainwright Sell
Nov-07-24 Upgrade Cantor Fitzgerald Neutral → Overweight
Oct-21-24 Initiated Jefferies Buy
Oct-10-24 Resumed Raymond James Outperform
Jul-29-24 Upgrade RBC Capital Mkts Sector Perform → Outperform
Jun-26-24 Downgrade Citigroup Buy → Neutral
May-31-24 Initiated Piper Sandler Overweight
May-28-24 Downgrade RBC Capital Mkts Outperform → Sector Perform
May-14-24 Upgrade Oppenheimer Perform → Outperform
Jan-31-24 Initiated BMO Capital Markets Outperform
Dec-13-23 Resumed Citigroup Buy
Dec-12-23 Initiated Deutsche Bank Buy
Nov-21-23 Initiated Wedbush Outperform
Oct-31-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Oct-31-23 Downgrade Oppenheimer Outperform → Perform
Jun-23-23 Downgrade Evercore ISI Outperform → In-line
Apr-26-23 Initiated SMBC Nikko Outperform
Apr-04-23 Initiated Citigroup Buy
Mar-01-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-22-22 Reiterated BTIG Research Buy
Dec-16-22 Upgrade UBS Neutral → Buy
Apr-04-22 Resumed Cantor Fitzgerald Overweight
Jan-05-22 Reiterated Needham Buy
Dec-09-21 Upgrade Oppenheimer Perform → Outperform
Nov-05-21 Upgrade JP Morgan Neutral → Overweight
Sep-15-21 Upgrade Guggenheim Neutral → Buy
Aug-05-21 Upgrade JP Morgan Underweight → Neutral
Jun-15-21 Initiated BTIG Research Buy
Apr-26-21 Resumed Credit Suisse Neutral
Jan-12-21 Downgrade Citigroup Buy → Neutral
Jan-11-21 Downgrade UBS Buy → Neutral
Jan-08-21 Downgrade JP Morgan Overweight → Underweight
Jan-08-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Jan-08-21 Downgrade Raymond James Outperform → Mkt Perform
Nov-11-20 Initiated Berenberg Hold
Oct-28-20 Initiated UBS Buy
Aug-25-20 Initiated Raymond James Outperform
Aug-20-20 Downgrade Credit Suisse Outperform → Neutral
Mar-31-20 Initiated Mizuho Buy
Nov-01-19 Initiated Guggenheim Buy
Aug-21-19 Reiterated Needham Buy
Jul-09-19 Reiterated Morgan Stanley Overweight
Jul-01-19 Reiterated RBC Capital Mkts Outperform
Apr-12-19 Initiated Evercore ISI Outperform
Mar-11-19 Reiterated Credit Suisse Outperform
Oct-12-18 Initiated Bernstein Outperform
Oct-01-18 Initiated Cantor Fitzgerald Overweight
Sep-26-18 Reiterated RBC Capital Mkts Outperform
Sep-14-18 Resumed BofA/Merrill Buy
Sep-06-18 Initiated Credit Suisse Outperform
Aug-01-18 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-21-18 Reiterated Robert W. Baird Outperform
Jun-20-18 Reiterated Needham Buy
Jun-19-18 Reiterated H.C. Wainwright Buy
View All

Sarepta Therapeutics Inc Stock (SRPT) Latest News

pulisher
12:17 PM

What drives Sarepta Therapeutics Inc. stock priceExceptional earning trajectories - PrintWeekIndia

12:17 PM
pulisher
Jul 20, 2025

Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) Shareholders of Class Action Lawsuit and August 25, 2025 Deadline - ACCESS Newswire

Jul 20, 2025
pulisher
Jul 20, 2025

What analysts say about Sarepta Therapeutics Inc. stockFree Stock Selection - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

Jul 20, 2025
pulisher
Jul 20, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Jul 20, 2025
pulisher
Jul 20, 2025

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire

Jul 20, 2025
pulisher
Jul 20, 2025

SRPT SECURITIES NEWS: Did Sarepta Therapeutics, Inc. - GlobeNewswire

Jul 20, 2025
pulisher
Jul 20, 2025

Q1 Earnings Estimate for SRPT Issued By Leerink Partnrs - Defense World

Jul 20, 2025
pulisher
Jul 20, 2025

Sarepta Therapeutics Inc. Stock Analysis and ForecastConsistently superior profits - Jammu Links News

Jul 20, 2025
pulisher
Jul 20, 2025

Sarepta Therapeutics’ (SRPT) Hold Rating Reiterated at Needham & Company LLC - Defense World

Jul 20, 2025
pulisher
Jul 20, 2025

StockWatch: Sarepta Shares Nosedive after LGMD Gene Therapy Patient Dies - Genetic Engineering and Biotechnology News

Jul 20, 2025
pulisher
Jul 19, 2025

This Gene Therapy Maker Refuses to Halt Shipments After Patient Deaths - Men's Journal

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline - Hoodline

Jul 19, 2025
pulisher
Jul 19, 2025

Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths - WTOP

Jul 19, 2025
pulisher
Jul 19, 2025

Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths - Yahoo Finance

Jul 19, 2025
pulisher
Jul 19, 2025

Gene Therapy Maker Sarepta Tells FDA It Won't Halt Shipments Despite Patient Deaths - U.S. News & World Report

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta Therapeutics lays off 500 employees amid FDA investigation, including 80 in Columbus - nbc4i.com

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta to continue Elevidys shipments despite FDA request to halt - Seeking Alpha

Jul 19, 2025
pulisher
Jul 19, 2025

Securities Fraud Litigation and Shareholder Returns: A Strategic Evaluation of Sarepta Therapeutics' ELEVIDYS Case - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

M&T Bank Corp Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta Therapeutics: A Sell Signal Amid Safety Crises and Existential Risks - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down Following Analyst Downgrade - Defense World

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Reaches New 52-Week Low Following Analyst Downgrade - Defense World

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys - Reuters

Jul 19, 2025
pulisher
Jul 18, 2025

Sarepta Therapeutics laying off nearly 500 employees, including 80 in Franklin County - 10TV

Jul 18, 2025
pulisher
Jul 18, 2025

Sarepta CEO: ‘We Have, I Believe, a Very Laudable History of Being Extraordinarily Transparent’ - MedCity News

Jul 18, 2025
pulisher
Jul 18, 2025

SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. - GlobeNewswire

Jul 18, 2025
pulisher
Jul 18, 2025

Is Sarepta Therapeutics Inc. a good long term investmentOutstanding capital growth - Jammu Links News

Jul 18, 2025
pulisher
Jul 18, 2025

Securities Fraud Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT)Levi & Korsinsky Reminds Investors of August 25, 2025 - ACCESS Newswire

Jul 18, 2025
pulisher
Jul 18, 2025

Sarepta receives FDA request to halt ELEVIDYS shipments for some patients - StreetInsider

Jul 18, 2025
pulisher
Jul 18, 2025

Sarepta Says Another Patient Died After Receiving Gene Therapy - Bloomberg.com

Jul 18, 2025
pulisher
Jul 18, 2025

FDA Shuts Down Sarepta's Distribution of Gene Therapy Elevidys Following Patient Deaths - NeurologyLive

Jul 18, 2025
pulisher
Jul 18, 2025

Sarepta Therapeutics Provides Statement on ELEVIDYS - Sarepta Therapeutics

Jul 18, 2025
pulisher
Jul 18, 2025

SRPTSarepta Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

Jul 18, 2025
pulisher
Jul 18, 2025

Gene-therapy company to eliminate 21 Durham employees as part of major restructuring - WRAL.com

Jul 18, 2025
pulisher
Jul 18, 2025

HHS Says FDA Requests Sarepta Therapeutics Suspend Distribution Of Elevidys And Places Clinical Trials On Hold For Multiple Gene Therapy Products Following 3 Deaths - TradingView

Jul 18, 2025
pulisher
Jul 18, 2025

FDA prepares to ask Sarepta Therapeutics to stop all shipments of Duchenne muscular dystrophy therapy - The Boston Globe

Jul 18, 2025
pulisher
Jul 18, 2025

SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Jul 18, 2025
pulisher
Jul 18, 2025

Exclusive-US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says - MarketScreener

Jul 18, 2025
pulisher
Jul 18, 2025

Exclusive: US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says - Reuters

Jul 18, 2025
pulisher
Jul 18, 2025

Sarepta Therapeutics laying off 80 employees in Ohio - WTTE

Jul 18, 2025
pulisher
Jul 18, 2025

Sarepta Therapeutics crisis is huge blow to Duchenne families, company - statnews.com

Jul 18, 2025
pulisher
Jul 18, 2025

Major biotech stock tumbles 35 percent after major rare disease setback - TheStreet

Jul 18, 2025
pulisher
Jul 18, 2025

Sarepta Crashes Almost 40% On A Damning Move From The FDA - Investor's Business Daily

Jul 18, 2025
pulisher
Jul 18, 2025

Elevidys' future said to be on ice after Sarepta reports patient death from separate gene therapy - FirstWord Pharma

Jul 18, 2025
pulisher
Jul 18, 2025

FDA to Ask Sarepta to Stop Shipping Muscular Dystrophy Drug Elevidys - The New York Times

Jul 18, 2025
pulisher
Jul 18, 2025

SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

Jul 18, 2025
pulisher
Jul 18, 2025

Investors Urged to Contact Levi & Korsinsky for Information Before August 25, 2025Sarepta Therapeutics, Inc. (SRPT) - TradingView

Jul 18, 2025
pulisher
Jul 18, 2025

Sarepta Stock (SRPT) Crashes 37% as FDA Scrutiny Mounts Over Gene Therapy Deaths - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Announces Third Death -- Contact BFA Law by the August 25 Class Action Deadline - GlobeNewswire

Jul 18, 2025
pulisher
Jul 18, 2025

Baird downgrades Sarepta Therapeutics stock rating on Elevidys safety concerns - Investing.com

Jul 18, 2025

Sarepta Therapeutics Inc Stock (SRPT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.88
price down icon 0.59%
$35.59
price up icon 0.34%
$102.56
price down icon 1.55%
$26.20
price down icon 5.18%
$110.02
price down icon 0.92%
biotechnology ONC
$294.55
price up icon 1.45%
Cap:     |  Volume (24h):